Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by EM Delicha
THU0369 Secukinumab 150mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis With High Retention Rate: 3-Year Results From Phase Iii Trial, Measure 2
Related publications
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results From the Phase 3 FUTURE 1 Study
ACR Open Rheumatology
Efficacy, Safety, and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis: A Randomized, Double-Blind Phase 3 Study, MEASURE 3
Arthritis Research & Therapy
FRI0494 Secukinumab Provides Rapid and Sustained Pain Relief in Psoriatic Arthritis: 2-Year Results From the Future 2 Study
Correction To: Secukinumab: A Review in Ankylosing Spondylitis
Drugs
Pharmacology
The High Prevalence of Infections and Allergic Symptoms in Patients With Ankylosing Spondylitis Is Associated With Clinical Symptoms
Clinical Rheumatology
Medicine
Rheumatology
The Advent of IL-17A Blockade in Ankylosing Spondylitis: Secukinumab, Ixekizumab and Beyond
Expert Review of Clinical Immunology
Allergy
Immunology
Sustained Response to Anakinra in Ankylosing Spondylitis
Rheumatology
Rheumatology
Pharmacology
Cost-Effectiveness Analysis of Secukinumab in Ankylosing Spondylitis: A Canadian Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Real-World Data on Secukinumab Use for Psoriatic Arthritis and Ankylosing Spondylitis
Therapeutic Advances in Musculoskeletal Disease
Rheumatology
Orthopedics
Sports Medicine
